# Creative Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/creative-bioscience

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.kangliming.com
- Total disclosed funding: $220M
- Latest round: Series D (Oct 14, 2021)
- Investors on record: 18

## About

Based in Guangzhou, China, and established in 2015, Creative Bioscience is a tumor early diagnosis product developer that focuses on intestinal cancer. It's business scope includes development, manufacturing and sales of in vitro diagnostic (IVD) products, and related technical services. It has four third-party medical testing laboratories in Guangzhou, Tianjin, Wuhan and Jinan. In 2020, it acquired Helixgen company, which strengthened its basic R&D ability and expand team.

The company provides vitro diagnostic (IVD) products, and related technical services. Diagnostics products includes human gene polymorphism test kit, gene mutation test kit. Lab services includes molecular diagnostics services. biology reagents includes HelixGen MHC tetramer, HelixGen MHC tetramer customization service.

The company plan to continue to develop early diagnosis products for high-incidence tumors, including lung cancer, bladder cancer, liver cancer, cervical cancer.

## Funding rounds

- Series D, Oct 14, 2021, $87M — IDG Capital, China Renaissance, CoStone Capital, Alibaba Entrepreneurs Fund, Henglu Asset Management, ABC International Capital
- Series C, Sep 27, 2020, $88M — CDH Investments, IDG Capital, Sharewin Investment, Jinkong Fund Management, Jundu Capital, Oceanpine Capital, Tsing Song Capital, Guangzhou Development District City Development Fund, Linden Asset Group, Think Real
- Series B, Apr 12, 2019, $45M — CDH Investments, IDG Capital, CD Capital
- Series A, Jul 13, 2017 — CD Capital, Qianhai Ark Capital
- Angel, Jan 12, 2015 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- CD Capital — Series A, Series B
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series A
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B, Series C
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B, Series C, Series D
- Sharewin Investment (https://capitalatlas.ai/funds/sharewin-investment) — Series C
- Jinkong Fund Management (https://capitalatlas.ai/funds/jinkong-fund-management) — Series C
- Jundu Capital (https://capitalatlas.ai/funds/jundu-capital) — Series C
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series C
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series C
- Guangzhou Development District City Development Fund (https://capitalatlas.ai/funds/guangzhou-development-district-city-development-fund) — Series C
- Linden Asset Group — Series C
- Think Real — Series C
- China Renaissance (https://capitalatlas.ai/funds/china-renaissance) — Series D
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series D
- Alibaba Entrepreneurs Fund (https://capitalatlas.ai/funds/alibaba-entrepreneurs-fund) — Series D
- Henglu Asset Management (https://capitalatlas.ai/funds/henglu-asset-management) — Series D
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series D